Advertisement

U.S. Markets open in 9 hrs 1 min

S&P Futures
5,886.25
-10.00(-0.17%)
Dow Futures
43,121.00
-56.00(-0.13%)
Nasdaq Futures
20,471.00
-48.50(-0.24%)
Russell 2000 Futures
2,249.70
-5.80(-0.26%)
Crude Oil
70.43
-0.13(-0.18%)
Gold
2,749.50
+10.60(+0.39%)

VYNE Therapeutics Inc. (VYNE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

2.4000

+0.1850

(+8.35%)

At close: 04:00PM EDT

2.4500

+0.05

(+2.08%)

After hours:

04:34PM EDT

Loading interactive chart...

Simply Wall St.
We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...
GlobeNewswire
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
VYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed on target engagement and inflammatory biomarkers Dosing has begun in the MAD portion of the trial with results expected in Q4 2024 BRIDGEWATER, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing